Company: OCEA
Filing Date: 2025-01-13
Form Type: 10-Q
Source: 0001493152-25-001880
Chunk: 173

Company: Ocean Biomedical, Inc.
Filing Date: 2025-01-13
Form: 10-Q
Item: Item 8
Chunk 173
---
 optimize value creation for each of our product candidates, and we intend to continuously assess the best pathway for each
as it progresses through the preclinical and clinical development process—including through internal advancement, partnerships
with established companies and spin-outs or other strategic transactions—in order to benefit patients through the commercialization
of these products. Our current active assets are licensed from Brown University and Rhode Island Hospital. Our scientific co-founders
and members of our Board of Directors (“Board”), Dr. Jack A. Elias and Dr. Jonathan Kurtis, are both affiliated with Brown
University and with Rhode Island Hospital. Our strategy is to accelerate the flow of the academic discoveries and the required clinical
development required for these product candidates and advance them commercially. The number of potential opportunities at research universities
and medical centers is large, but only a small fraction of these opportunities is currently tapped in the market. The gap remains wide
and we believe this presents an attractive opportunity for us to become an industry leader by addressing a need to accelerate the advancement
of therapeutics that can address significant unmet medical needs. The core elements that we believe differentiate our business model
include:

    ●
    Harnessing inventions
    and technologies from research universities and medical centers. We are experienced at identifying and sourcing breakthrough
    discoveries at academic and research institutions, including our current partnerships with Brown University and Rhode Island Hospital.

35

    ●
    Developing new drug
    therapies through an operationally efficient, evidence-based and milestone- driven approach. Once we select an asset for development,
    we pursue what we believe are appropriate development strategies that we aim to execute efficiently by leveraging contract research
    organizations (“CROs”) and contract manufacturing organizations (“CMOs”), and other drug development experts
    and consultants.

    ●
    Building a diverse portfolio
    of product candidates. We are evidence-based and program agnostic, meaning that our resources are driven strictly by program
    progress and milestone achievements. Our approach is to develop multiple diverse programs in parallel which mitigates business risk.

    ●
    Providing attractive
    economic upside to our partners at research universities and medical centers. We have a structure wherein our parent company
    houses each program in a subsidiary. We believe this structure is optimal to provide attractive economic incentives to the discovering
    institution and its researchers.

    ●
    Employing a multi-disciplinary
    approach to drug discovery and development across our programs. Our business model is based on bringing together the appropriate
    disciplines and expertise needed for each of